On December 23, 2025, the US Department of Health and Human Services (HHS) issued a request for information (RFI) to solicit proposals to accelerate the adoption of artificial intelligence (AI) in clinical care[1][3][4][5]. The RFI focuses on three main levers: regulation, reimbursement and research and development[1][2][5]. According to comments from health technology companies and organizations such as Epic, Oracle and AHA, HHS should align regulations with existing frameworks, introduce financial incentives and reimbursement for AI tools[2][3][4]. Responses highlight the need to include clinicians in the AI decision-making process, uniform privacy and security standards for vendors, as well as risk-based post-market standards for AI devices[2]. The American Society of Clinical Oncology (ASCO) and other associations are proposing training, simplification of regulatory processes, and prioritization of research to validate AIs in various populations[3][6]. By 23 February 2026, approximately 7,000 comments have been submitted, forming an industry wish list to support AI in practice[3][4]. These proposals build on HHS's December 2025 AI Strategy and the goal of reducing regulatory barriers[1][3].